Back

Zoetis Inc

Ticker: ZTS ISIN: US98978V1035
Add to portfolio Portfolio analysis in 2min
Stock Large-cap Dividend payer
Market cap
$49.95B
P/E
18.83
Forward P/E
16.47
Profit margin
28.24%
Revenue growth QoQ
3.00%
Div. yield
1.71%
Beta
0.95
$71.33 -0.10%
Price as of 2026-09-21 · NYSE

Performance by timeframe

Rolling returns
1 Month -7.57%
6 Months -37.77%
1 Year -49.74%
5 Years -18.11% p.a.-63.14%
10 Years +4.28% p.a.+52.06%
Since inception +7.21% p.a.+158.41%
Calendar year returns
YTD -42.42%
2025 -21.75%
2024 -16.63%
2023 +35.91%
2022 -39.51%
2021 +48.26%

Key stats

Market cap
49.95B
P/E
18.83
Dividend yield
1.71%
Beta
0.95
52-week range
113.29 - 170.33
50-day MA
124.41
200-day MA
138.35
Section 1

Business overview

Company profile data from fundamentals.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally. The company commercializes products primarily across companion animals comprising dogs, cats, and horses; and species, including livestock, such as cattle, swine, poultry, fish, and sheep. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaborated with Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was incorporated in 2012 and is headquartered in Parsippany, New Jersey.

Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Country United States
Exchange NYSE
Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 65.99%
ROA 15.26%
Profit margin 28.24%
Operating margin 34.69%
PEG ratio 1.87
Revenue/share TTM 21.35
Revenue TTM 9.47B
EBITDA 4.07B
Gross profit TTM 6.81B
Beta 0.95

Valuation

Trailing P/E 18.83
Forward P/E 16.47
P/B 14.66
P/S 5.28
EV/EBITDA 13.70
EV/Revenue 5.89
Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 7.03
Quarterly earnings growth 6.10%
Revenue TTM 9.47B
Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 1.71%
Dividend per share 2.0000
Next dividend date 2026-06-02
Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Ownership & short interest

Short ratio 3.92
Short % of float 3.72%

Details

Instrument metadata and source update timestamps.

Symbol ZTS
Name Zoetis Inc
Asset type STOCK
Exchange NYSE
Currency USD
ISIN US98978V1035
Country USA
Code + exchange ZTS.NYSE
Last price date 2026-03-27
Fundamentals updated 2026-03-28

The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.

Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.

Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.

Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.

By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.

Instrument logos provided by Elbstream.